Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
Status:
Recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well niraparib, when given before surgery, works in treating
patients with high risk prostate cancer that has not spread to other parts of the body
(localized) and alterations in deoxyribonucleic acid (DNA) repair pathways. Niraparib may
stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.